Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units

This study has been completed.

First Received on September 11, 2005. Last Updated on March 14, 2007 History of Changes

Sponsor:	Wyeth is now a wholly owned subsidiary of Pfizer
Information provided by:	Wyeth is now a wholly owned subsidiary of Pfizer
ClinicalTrials.gov Identifier:	NCT00167999

Purpose

To determine the value of increasing use of piperacillin/tazobactam as empiric therapy and restricting extended-spectrum cephalosporins in reducing the cases of ESBL producing Escherichia coli and Klebsiella pneumoniae in hematology and oncology units

Condition	Intervention	Phase
Gram-Positive Bacterial Infections Escherichia Coli Infections Klebsiella Infections	Drug: piperacillin-tazobactam	Phase IV

Study Type:	Observational
Study Design:	Observational Model: Case Control Observational Model: Natural History Time Perspective: Longitudinal Time Perspective: Prospective
Official Title:	Effects of Piperacillin-Tazobactam Use on the Prevalence Rate of Extended-Spectrum Beta-Lactamase (ESBL) Producing Escherichia Coli and Klebsiella Pneumoniae in Hematology and Oncology Units.

Resource links provided by NLM:

MedlinePlus related topics: Bacterial Infections E. Coli Infections Pneumonia

Drug Information available for: Piperacillin sodium Piperacillin Tazobactam Zosyn

U.S. FDA Resources

Further study details as provided by Wyeth is now a wholly owned subsidiary of Pfizer:

Estimated Enrollment:	200
Study Start Date:	February 2005

Eligibility

Ages Eligible for Study:	15 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Eligible patients of either sex, 15 years of age or older
Patients who are admitted to the department of hematology and oncology
Provide written informed consent

Exclusion Criteria:

Patients who have hypersensitivity to β-lactam antibiotics
Female who are pregnant or breast-feeding
Any underlying conditions or non-infectious diseases that will be ultimately fatal within 30 days

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00167999

Locations

Korea, Republic of

Seoul, Korea, Republic of, 133-792

Sponsors and Collaborators

Wyeth is now a wholly owned subsidiary of Pfizer

Investigators

Study Director:

Medical Monitor

Wyeth is now a wholly owned subsidiary of Pfizer

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00167999 History of Changes
Other Study ID Numbers:	0910X-101676
Study First Received:	September 11, 2005
Last Updated:	March 14, 2007
Health Authority:	Korea: Food and Drug Administration

Keywords provided by Wyeth is now a wholly owned subsidiary of Pfizer:

Bacterial Infections

Additional relevant MeSH terms:

Bacterial Infections
Escherichia coli Infections
Klebsiella Infections
Gram-Positive Bacterial Infections
Enterobacteriaceae Infections
Gram-Negative Bacterial Infections
Piperacillin
Penicillanic Acid

Piperacillin-tazobactam combination product
Tazobactam
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on February 12, 2012